Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Net Margin (2022 - 2025)

Bioregenx (BRGX) has 4 years of Net Margin data on record, last reported at 15.87% in Q3 2025.

  • For Q3 2025, Net Margin rose 5038.0% year-over-year to 15.87%; the TTM value through Sep 2025 reached 980.96%, down 79357.0%, while the annual FY2024 figure was 985.17%, 96479.0% down from the prior year.
  • Net Margin reached 15.87% in Q3 2025 per BRGX's latest filing, up from 39.99% in the prior quarter.
  • Across five years, Net Margin topped out at 0.47% in Q2 2023 and bottomed at 3995.88% in Q4 2024.
  • Average Net Margin over 4 years is 391.02%, with a median of 62.09% recorded in 2022.
  • Peak YoY movement for Net Margin: plummeted -397533bps in 2024, then surged 52184bps in 2025.
  • A 4-year view of Net Margin shows it stood at 62.09% in 2022, then surged by 67bps to 20.55% in 2023, then plummeted by -19346bps to 3995.88% in 2024, then soared by 100bps to 15.87% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 15.87% in Q3 2025, 39.99% in Q2 2025, and 51.8% in Q1 2025.